Clinical Trials For Psoriasis and Psoriatic Disorders

This study will evaluate the use of Enbrel (etanercept) to treat psoriasis for a period of up to one year. Candidates 18 or older with moderate-to-severe plaque psoriasis who are able to start Enbrel therapy as prescribed may be eligible. People with skin conditions other than psoriasis that would interfere with study evaluations, or people taking Remicade (infliximab), Humira (adalimumab) or Amevive (alefacept) will not qualify. Research sites are located throughout Canada.